TMO - Thermo Fisher Scientific Inc Stock Price, Fair Value and News

577.72USD+3.13 (+0.54%)Market Closed

Market Summary

USD577.72+3.13

Market Closed

0.54%

TMO Stock Price

View Fullscreen

TMO RSI Chart

TMO Valuation

Market Cap

220.3B

Price/Earnings (Trailing)

36.99

Price/Sales (Trailing)

5.14

EV/EBITDA

27.86

Price/Free Cashflow

31.8

TMO Price/Sales (Trailing)

TMO Profitability

EBT Margin

14.70%

Return on Equity

12.74%

Return on Assets

6.03%

Free Cashflow Yield

3.14%

TMO Fundamentals

TMO Revenue

Revenue (TTM)

42.9B

Rev. Growth (Yr)

-4.93%

Rev. Growth (Qtr)

2.95%

TMO Earnings

Earnings (TTM)

6.0B

Earnings Growth (Yr)

2.03%

Earnings Growth (Qtr)

-5.25%

Breaking Down TMO Revenue

Last 7 days

5.6%

Last 30 days

0.7%

Last 90 days

7.3%

Trailing 12 Months

5.4%

How does TMO drawdown profile look like?

TMO Financial Health

Current Ratio

1.75

Debt/Equity

0.67

Debt/Cashflow

0.27

TMO Investor Care

Dividend Yield

0.24%

Dividend/Share (TTM)

1.4

Buy Backs (1Y)

1.07%

Diluted EPS (TTM)

15.45

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	43.8B	43.5B	43.4B	42.9B
2022	41.1B	42.8B	44.2B	44.9B
2021	35.9B	38.3B	39.1B	39.2B
2020	25.6B	26.2B	28.5B	32.2B
2019	24.6B	24.9B	25.2B	25.5B
2018	22.0B	23.1B	23.9B	24.4B
2017	18.7B	19.2B	19.8B	20.9B
2016	17.3B	17.6B	18.0B	18.3B
2015	16.9B	16.9B	16.8B	17.0B
2014	13.8B	14.9B	15.9B	16.9B
2013	12.6B	12.8B	12.9B	13.1B
2012	11.9B	12.2B	12.3B	12.5B
2011	10.5B	10.8B	11.1B	11.6B
2010	10.3B	10.4B	10.5B	10.4B
2009	10.0B	9.7B	9.6B	9.9B
2008	0	9.9B	10.1B	10.3B
2007	0	0	0	9.7B

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed S&P 500 Index

Grufity's Fair Value model takes all the S&P 500 stocks and divides them into separate buckets based on their attractiveness. The 'Very Cheap' bucket of S&P 500 has greatly outperformed S&P 500 Index. Conversely, S&P500 stocks considered 'Very Expensive' by the model underperformed the S&P500 index in the past three years. Grufity Fair Value is available for 2300+ stocks, including 90% of S&P 500 stocks. Grufity's Fair Value Model separates high-return stocks from low-return stocks.

Returns of $10,000 invested in:

Very Cheap Stocks: $17,289
S&P 500 Index: $12,922
Very Expensive Stocks: $11,022

Grufity's Fair Value model does a great job in separating High Performing Stocks from Low Performing ones in the S&P 500 list.

S&P 500 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Thermo Fisher Scientific Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 25, 2024	holmes joseph r.	acquired	-	-	46.00	vp & chief accounting officer
Mar 13, 2024	casper marc n	acquired	1,905,900	190	10,000	chairman & ceo
Mar 13, 2024	casper marc n	sold	-5,945,760	594	-10,000	chairman & ceo
Mar 12, 2024	britt lisa p.	acquired	2,852,540	198	14,345	sr. vp and chief hr officer
Mar 12, 2024	britt lisa p.	sold	-8,591,220	598	-14,345	sr. vp and chief hr officer
Mar 12, 2024	casper marc n	sold	-5,979,760	597	-10,000	chairman & ceo
Mar 12, 2024	casper marc n	acquired	1,905,900	190	10,000	chairman & ceo
Mar 11, 2024	casper marc n	acquired	1,905,900	190	10,000	chairman & ceo
Mar 11, 2024	casper marc n	sold	-5,953,600	595	-10,000	chairman & ceo
Mar 11, 2024	casper marc n	gifted	-	-	-2,000	chairman & ceo

Which funds bought or sold TMO recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 23, 2024	DeDora Capital, Inc.	reduced	-29.26	-204,418	702,919	0.22%
Apr 23, 2024	McAdam, LLC	sold off	-100	-209,662	-	-%
Apr 23, 2024	United Asset Strategies, Inc.	added	4.94	1,842,360	14,200,900	1.42%
Apr 23, 2024	Main Street Financial Solutions, LLC	reduced	-1.41	75,224	1,018,530	0.11%
Apr 23, 2024	Shepherd Financial Partners LLC	new	-	254,571	254,571	0.03%
Apr 23, 2024	Hunter Perkins Capital Management, LLC	sold off	-100	-2,654,000	-	-%
Apr 23, 2024	BANK OF STOCKTON	added	0.79	12,909	222,022	0.07%
Apr 23, 2024	REGIONS FINANCIAL CORP	reduced	-4.23	3,426,680	73,764,800	0.56%
Apr 23, 2024	Global Retirement Partners, LLC	added	1.9	335,968	3,956,800	0.15%
Apr 23, 2024	Strategic Investment Advisors / MI	added	26.07	206,327	750,086	0.10%

Are Funds Buying or Selling TMO?

Are funds buying TMO calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own TMO

No. of Funds

Unveiling Thermo Fisher Scientific Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	vanguard group inc	8.54%	32,977,462	SC 13G/A
Feb 08, 2024	blackrock inc.	-	0	SC 13G/A
Feb 08, 2024	blackrock inc.	7.3%	28,329,861	SC 13G/A
Feb 09, 2023	vanguard group inc	8.30%	32,534,676	SC 13G/A
Feb 03, 2023	blackrock inc.	7.9%	30,790,122	SC 13G/A
Feb 10, 2022	vanguard group inc	7.89%	31,103,788	SC 13G/A
Feb 01, 2022	blackrock inc.	7.9%	30,982,611	SC 13G
Feb 10, 2021	vanguard group inc	7.82%	30,997,381	SC 13G/A
Feb 01, 2021	blackrock inc.	7.4%	29,504,221	SC 13G/A
Feb 12, 2020	vanguard group inc	7.77%	31,187,697	SC 13G/A

Recent SEC filings of Thermo Fisher Scientific Inc

View All Filings

Date Filed	Form Type	Document
Apr 24, 2024	8-K	Current Report
Apr 24, 2024	SC TO-T/A	SC TO-T/A
Apr 09, 2024	ARS	ARS
Apr 09, 2024	DEF 14A	DEF 14A
Apr 09, 2024	DEFA14A	DEFA14A
Apr 02, 2024	4	Insider Trading
Apr 02, 2024	4	Insider Trading
Apr 02, 2024	4	Insider Trading
Apr 02, 2024	4	Insider Trading
Mar 27, 2024	4	Insider Trading

Peers (Alternatives to Thermo Fisher Scientific Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
DHR	174.4B	23.7B	1.02%	7.91%	39.62	7.35	-8.94%	-35.72%
IDXX	41.1B	3.7B	-6.67%	2.31%	48.61	11.22	8.72%	24.44%
A	40.3B	6.7B	-5.56%	5.45%	32.59	5.98	-2.81%	-6.58%
DGX	14.3B	9.3B	6.43%	-6.08%	16.85	1.54	-3.29%	6.68%
CRL	12.3B	4.1B	-9.86%	27.62%	25.9	2.98	3.86%	-2.39%
MEDP	11.5B	2.0B	-1.17%	90.89%	36.88	5.87	25.57%	21.62%
EXAS	11.5B	2.5B	-0.82%	-0.49%	-56.23	4.59	19.93%	67.26%
NTRA	11.0B	1.1B	0.12%	80.51%	-25.41	10.21	31.99%	20.63%
MID-CAP
NEOG	2.7B	929.2M	-18.50%	-26.31%	1.7K	2.89	28.93%	111.61%
GH	2.2B	563.9M	5.66%	-15.62%	-4.59	3.91	25.45%	26.76%
SMALL-CAP
CDNA	413.2M	280.3M	-17.90%	-0.25%	-2.17	1.47	-12.89%	-148.37%
ACRS	83.0M	31.2M	0.86%	-86.93%	-0.94	2.66	5.03%	-1.81%
AWH	42.0M	9.2M	-4.49%	-35.24%	-2.51	4.58	11.85%	44.12%
APDN	4.1M	9.0M	-50.00%	-75.76%	-0.56	0.45	-53.31%	2.21%
BIOC	183.8K	25.9M	-50.00%	-94.83%	-0.01	0.01	-57.78%	-93.11%

Thermo Fisher Scientific Inc News

Latest updates

Thermo Fisher Scientific Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Income Statement (Quarterly)																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	3.0%	10,886	10,574	10,687	10,710	11,450	10,677	10,970	11,818	10,702	9,330	9,273	9,906	10,550	8,521	6,917	6,230	6,829	6,272	6,316	6,125	6,507
Costs and Expenses	3.7%	9,032	8,710	9,109	9,147	9,589	8,967	8,969	8,997	8,164	7,052	7,110	6,857	7,479	6,095	5,526	5,324	5,597	5,326	4,820	5,205	5,359
S&GA Expenses	4.1%	2,132	2,049	2,145	2,119	2,299	2,208	2,209	2,277	2,278	2,004	1,899	1,826	2,077	1,592	1,710	1,551	1,512	1,539	1,565	1,528	1,510
R&D Expenses	2.5%	327	319	345	346	391	351	365	364	392	351	343	320	376	296	264	245	262	247	246	248	251
EBITDA Margin	2.5%	0.20*	0.20*	0.19*	0.19*	0.21*	0.21*	0.23*	0.24*	0.26*	0.29*	0.29*	0.29*	0.26*	0.23*	0.19*	0.21*	0.21*	0.21*	0.21*	-	-
Interest Expenses	8.6%	390	359	326	300	269	173	148	136	161	128	122	125	146	144	137	126	142	164	181	189	-
Income Taxes	150.9%	133	53.00	52.00	46.00	173	31.00	198	301	203	271	219	416	394	319	97.00	40.00	36.00	62.00	274	2.00	114
Earnings Before Taxes	-1.4%	1,740	1,765	1,430	1,363	1,777	1,601	1,917	2,540	1,862	2,177	2,049	2,753	2,897	2,252	1,253	828	1,040	822	1,393	817	1,012
EBT Margin	0.7%	0.15*	0.15*	0.14*	0.15*	0.17*	0.18*	0.20*	0.21*	0.23*	0.25*	0.26*	0.26*	0.22*	0.19*	0.15*	0.16*	0.16*	0.16*	0.16*	-	-
Net Income	-5.3%	1,606	1,695	1,362	1,292	1,574	1,498	1,668	2,220	1,659	1,903	1,829	2,337	2,500	1,933	1,156	788	1,002	760	1,119	815	898
Net Income Margin	1.9%	0.14*	0.14*	0.13*	0.14*	0.15*	0.16*	0.17*	0.19*	0.20*	0.22*	0.22*	0.22*	0.20*	0.17*	0.14*	0.14*	0.14*	0.14*	0.14*	-	-
Free Cashflow	59.4%	3,318	2,082	1,256	271	2,937	1,390	1,022	1,562	1,626	2,126	1,687	1,350	2,753	2,342	1,617	103	1,624	901	1,074	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	1.7%	98,726	97,057	94,105	94,658	97,154	90,536	90,579	92,747	95,123	73,600	67,698	65,931	69,052	64,061	61,593	58,688	58,381	56,729	57,970	55,596	56,232
Current Assets	6.5%	24,589	23,092	19,995	20,209	25,229	19,299	18,100	18,776	20,113	24,724	19,260	17,685	21,957	18,234	15,775	12,738	11,893	10,514	11,223	9,939	10,625
Cash Equivalents	31.3%	8,077	6,151	3,133	3,482	8,524	2,934	1,905	2,779	4,491	12,048	7,035	5,603	10,336	7,570	5,837	3,010	2,422	1,305	2,314	1,128	2,117
Inventory	-5.8%	5,088	5,404	5,655	5,664	5,634	5,722	5,668	5,483	5,051	4,906	4,625	4,342	4,029	3,829	3,648	3,454	3,370	3,308	3,209	3,124	3,005
Net PPE	3.1%	9,448	9,167	9,292	9,354	9,280	8,628	8,529	8,448	8,333	7,049	6,560	6,133	5,912	5,180	4,887	4,736	4,749	4,420	4,394	4,192	4,165
Goodwill	1.0%	44,020	43,583	43,273	43,140	41,196	40,488	41,066	41,721	41,924	26,909	26,904	26,823	26,041	25,782	25,700	25,614	25,714	25,624	25,757	25,236	25,347
Current Liabilities	-1.0%	14,012	14,158	14,112	15,884	17,010	11,118	10,997	12,070	13,436	7,753	6,925	6,995	10,304	6,228	6,013	5,500	6,197	5,844	7,509	5,898	6,147
Long Term Debt	2.7%	31,308	30,489	29,194	29,135	28,909	28,150	29,250	31,389	32,333	21,688	18,773	18,641	19,107	21,091	20,638	19,231	17,076	16,392	16,663	16,812	17,719
LT Debt, Non Current	-	-	-	-	-	-	-	-	-	-	-	18,773	18,641	19,107	21,091	20,638	19,231	17,076	16,392	-	-	17,719
Shareholder's Equity	3.1%	46,735	45,328	43,802	42,310	43,978	43,608	42,354	41,018	40,855	38,757	36,901	35,068	34,517	31,824	29,875	28,559	29,684	29,355	28,729	27,693	27,594
Retained Earnings	3.3%	47,364	45,869	44,289	43,064	41,910	40,452	39,074	37,528	35,431	33,876	32,076	30,350	28,116	25,705	23,860	22,791	22,092	21,165	20,482	19,439	18,696
Additional Paid-In Capital	0.7%	17,286	17,165	17,030	16,889	16,743	16,596	16,467	16,292	16,174	15,960	15,826	15,684	15,579	15,467	15,334	15,186	15,064	14,964	14,887	14,771	14,621
Shares Outstanding	0%	386	386	386	386	392	392	392	392	394	394	393	394	396	396	395	397	400	400	400	-	-
Minority Interest	-161.1%	-11.00	18.00	50.00	53.00	54.00	59.00	61.00	62.00	62.00	-	-	-	10.00	-	-	-	-	-	-	-	-
Float	-	-	-	201,177	-	-	-	214,582	-	-	-	201,672	-	-	-	138,640	-	-	-	117,442	-	-

Cashflow (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Cashflow (Quarterly)																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	54.2%	3,723	2,414	1,540	729	3,487	1,937	1,528	2,202	2,457	2,650	2,227	1,978	3,339	2,708	1,886	356	1,913	1,117	1,294	649	1,801
Share Based Compensation	-9.0%	61.00	67.00	74.00	76.00	75.00	77.00	77.00	78.00	77.00	51.00	51.00	51.00	51.00	52.00	47.00	46.00	43.00	42.00	52.00	44.00	44.00
Cashflow From Investing	68.2%	-376	-1,181	-443	-3,142	-525	-545	-419	-670	-18,692	-616	-626	-1,998	-626	-365	-259	-260	-339	-198	-769	-181	-721
Cashflow From Financing	-177.0%	-1,428	1,855	-1,456	-2,593	2,391	-151	-1,905	-3,145	8,467	3,040	-76.00	-4,850	-49.00	-791	1,180	619	-514	-1,869	690	-1,425	-13.00
Dividend Payments	0.7%	136	135	135	117	117	118	117	103	103	102	103	87.00	87.00	87.00	87.00	76.00	76.00	77.00	76.00	68.00	68.00
Buy Backs	-	-	-	-	3,000	1,000	-	-	2,000	-	-	-	2,000	-	-	-	1,500	750	-	-	750	250

TMO Income Statement

2023-12-31

Consolidated Statement of Income - USD ($) shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Revenues
Revenues	$ 42,857	$ 44,915	$ 39,211
Costs and operating expenses:
Selling, general and administrative expenses	8,445	8,993	8,007
Research and development expenses	1,337	1,471	1,406
Restructuring and other costs	459	114	197
Total costs and operating expenses	35,998	36,522	29,183
Operating income	6,859	8,393	10,028
Interest income	879	272	43
Interest expense	(1,375)	(726)	(536)
Other income/(expense)	(65)	(104)	(694)
Income before income taxes	6,298	7,835	8,841
Provision for income taxes	(284)	(703)	(1,109)
Equity in earnings/(losses) of unconsolidated entities	(59)	(172)	(4)
Net income	5,955	6,960	7,728
Less: net (losses) income attributable to noncontrolling interests and redeemable noncontrolling interest	(40)	10	3
Net income attributable to Thermo Fisher Scientific Inc.	$ 5,995	$ 6,950	$ 7,725
Earnings per share attributable to Thermo Fisher Scientific Inc.
Basic (in dollars per share)	$ 15.52	$ 17.75	$ 19.62
Diluted (in dollars per share)	$ 15.45	$ 17.63	$ 19.46
Weighted average shares
Basic (in shares)	386	392	394
Diluted (in shares)	388	394	397
Product revenues
Revenues
Revenues	$ 25,243	$ 28,548	$ 30,361
Costs and operating expenses:
Cost of revenues	13,168	14,247	13,594
Service revenues
Revenues
Revenues	17,614	16,367	8,850
Costs and operating expenses:
Cost of revenues	$ 12,589	$ 11,697	$ 5,979

TMO Balance Sheet

2023-12-31

Consolidated Balance Sheet - USD ($) $ in Millions	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 8,077	$ 8,524
Accounts receivable, less allowances of $193 and $189	8,221	8,115
Inventories	5,088	5,634
Contract assets, net	1,443	1,312
Other current assets	1,760	1,644
Total current assets	24,589	25,229
Property, plant and equipment, net	9,448	9,280
Acquisition-related intangible assets, net	16,670	17,442
Other assets	3,999	4,007
Goodwill	44,020	41,196
Total assets	98,726	97,154
Current liabilities:
Short-term obligations and current maturities of long-term obligations	3,609	5,579
Accounts payable	2,872	3,381
Accrued payroll and employee benefits	1,596	2,095
Contract liabilities	2,689	2,601
Other accrued expenses	3,246	3,354
Total current liabilities	14,012	17,010
Deferred income taxes	1,922	2,849
Other long-term liabilities	4,642	4,238
Long-term obligations	31,308	28,909
Commitments and Contingencies
Redeemable noncontrolling interest	118	116
Thermo Fisher Scientific Inc. shareholders’ equity:
Preferred stock, $100 par value, 50,000 shares authorized; none issued
Common stock, $1 par value, 1,200,000,000 shares authorized; 442,188,634 and 440,668,112 shares issued	442	441
Capital in excess of par value	17,286	16,743
Retained earnings	47,364	41,910
Treasury stock at cost, 55,541,290 and 50,157,275 shares	(15,133)	(12,017)
Accumulated other comprehensive income/(loss)	(3,224)	(3,099)
Total Thermo Fisher Scientific Inc. shareholders’ equity	46,735	43,978
Noncontrolling interests	(11)	54
Total equity	46,724	44,032
Total liabilities, redeemable noncontrolling interest and equity	$ 98,726	$ 97,154

About Thermo Fisher Scientific Inc

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the United States and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, clinical next-generation sequencing, bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Biopharma Services segment provides laboratory products, laboratory chemicals, research and safety market channel, and pharma services and clinical research. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.

CEO	Mr. Marc N. Casper
WEBSITE	thermofisher.com
INDUSTRY	Diagnostics & Research
EMPLOYEES	65535

Thermo Fisher Scientific Inc Frequently Asked Questions

What is the ticker symbol for Thermo Fisher Scientific Inc? What does TMO stand for in stocks?

TMO is the stock ticker symbol of Thermo Fisher Scientific Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Thermo Fisher Scientific Inc (TMO)?

As of Wed Apr 24 2024, market cap of Thermo Fisher Scientific Inc is 220.29 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of TMO stock?

You can check TMO's fair value in chart for subscribers.

What is the fair value of TMO stock?

You can check TMO's fair value in chart for subscribers. The fair value of Thermo Fisher Scientific Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Thermo Fisher Scientific Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for TMO so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Thermo Fisher Scientific Inc a good stock to buy?

The fair value guage provides a quick view whether TMO is over valued or under valued. Whether Thermo Fisher Scientific Inc is cheap or expensive depends on the assumptions which impact Thermo Fisher Scientific Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for TMO.

What is Thermo Fisher Scientific Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Apr 24 2024, TMO's PE ratio (Price to Earnings) is 36.99 and Price to Sales (PS) ratio is 5.14. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TMO PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Thermo Fisher Scientific Inc's stock?

In the past 10 years, Thermo Fisher Scientific Inc has provided 0.179 (multiply by 100 for percentage) rate of return.